GlassScriptPhysician profile
Lakshmi V Tenneti
NPI 1598944571
$3,325.79
in general payments reported to CMS, 2019-2025
21 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $50.74 · 2021: $388 · 2022: $583 · 2023: $1,107 · 2024: $545 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989 · Education: $24.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.89 |
| Education | $24.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $656.54 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $492.69 | 2020-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $400.20 | 2019-2024 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $395.35 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $258.38 | 2022-2025 | Filspari |
| Medtronic, INC. | $164.56 | 2023-2024 | Endo Gia Ultra, Ellipsys Vascular Access System |
| Ani Pharmaceuticals, INC. | $155.36 | 2023-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $144.06 | 2024-2025 | |
| Amgen INC. | $137.80 | 2019 | |
| Outset Medical INC | $125.00 | 2023 | |
| Fresenius USA Marketing, INC. | $115.01 | 2019-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $76.42 | 2019-2024 | Jynarque |
| Mallinckrodt Enterprises LLC | $40.67 | 2019 | |
| Novo Nordisk INC | $25.19 | 2025 | |
| Opko Pharmaceuticals, LLC | $22.56 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $21.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.63 | 2024 | Jardiance |
| Dexcom, INC. | $20.19 | 2025 | Dexcom G6 Transmitter |
| Calliditas Therapeutics US INC. | $20.11 | 2025 | Tarpeyo |
| Scpharmaceuticals INC. | $19.93 | 2025 | |
| Glaxosmithkline, LLC. | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakshmi Tenneti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.